Clinical Trial Finder

Inclusion Criteria:

• - Prior diagnosis of multiple myeloma as defined by IMWG criteria.

• - Measurable disease based on IMWG criteria as defined by at least 1 of the following: - Serum M-protein ≥0.5 g/dL by SPEP.

• - Urinary M-protein excretion ≥200 mg/24 hour by UPEP.

• - Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FL ratio (<0.26 or >1.65) - Part 1: Received 2-4 prior lines of therapy for multiple myeloma, consisting of at least 1 immunomodulatory drug and 1 proteasome inhibitor.

• - Part 2: Received 1-3 prior lines of therapy for multiple myeloma, consisting of at least 1 immunomodulatory drug and 1 proteasome inhibitor.

• - ECOG performance status 0-1.

• - Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1.

Exclusion Criteria:

• - Plasma cell leukemia, Smoldering multiple myeloma, Waldenström's macroglobulinemia, Amyloidosis, POEMS Syndrome.

• - Impaired cardiovascular function or clinically significant cardiovascular diseases.

• - Stem cell transplant within 12 weeks prior to enrollment or active graft vs.host disease.

• - Participants with any active, uncontrolled bacterial, fungal, or viral infection.

• - Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.

• - Previous treatment with: - BCMA-directed or CD3 redirecting therapy.

• - Iberdomide (CC-220) or Mezigdomide.

• - Administration of strong inhibitor or inducer of CYP3A4/5 within 2 weeks prior to dosing and during the study.

• - Administration with an investigational product within 30 days preceding the first dose of study intervention.

Arms

Interventions